Greetings and welcome to our regular HotCopper Highlights segment, wrapping all the Australian stock action from Week 13. I’m Isaac McIntyre, and in this segment, The Market Link looks at the market news and company announcements you were watching this week on Australia’s #1 finance website.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Let’s get straight into it, starting with the most viewed, where Amplitude Energy (ASX:AEL) leads the way. I recently called Amplitude the “main character of the day” on Wednesday after it popped up in every single column and summary write-up I had to do (with Jonathon Davidson away, I’ve been busy!)
That’s carried on to the end of WK13, too, with Amplitude far and away one of the most watched stocks on the HotCopper forums. I’ve covered this producer ad nauseam through the week, so here’s the short and narrow: The company just confirmed its Isabella gas discovery in the offshore Otway Basin will “not be commercially viable,” after wrapping up a critical flow test on-site.
Elsewhere, Amplia Therapeutics (ASX:ATX) has hit 23cps, and HotCopper users are paying attention. Amplia has just recently landed several positive complete responses from five patients living with pancreatic cancer.
And finally, among the most watched was new gold producer New Murchison Gold (ASX:NMG), which has sagged -35% in the last month as traders dump shiny gold for the new oil “meme trade.” Still up +180% YoY, though. This is an interesting one because New Murchison has been delivering again and again at Crown Prince, but sinking bullion prices have temporarily killed hype.
Now, for the most discussed. Woodside Energy (ASX:WDS) has been a breakaway, with the rollercoaster Energy story in WK13 impacting our big Aussie producer quite a bit. On Friday, Woodside is up nearly +1% at time of writing; that’s mainly been helped by traders everywhere souring on bets for peace.
Clarity Pharmaceuticals (ASX:CU6) deserves a mention here, too, after landing a large-scale manufacturing supply agreement for its copper-64 isotope, a crucial component for its lead prostate cancer agent, 64Cu-SAR-bisPSMA. The deal has been signed with Theragenics and aims to ensure a robust supply chain for its novel radiopharmaceuticals. CU6 shares are down somewhat this week, though, -7% weaker.
And, 4DMedical (ASX:4DX) has popped up as one of the most discussed again. No surprise, considering how loved 4DX is across the HotCopper forums and in other Oz trading ports on the internet, but a +67% bump (to add to its +2,087% year return) means shareholders are happy heading into the weekend.
So, that’s HotCopper Highlights for Week 13 of the year. I’m Isaac McIntyre, have a great weekend, and see you bright and early Monday.
Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.